ΑΡΧΕΙΟ ΑΝΑΡΤΗΣΕΩΝ ΤΟΥ MACEDOINE BLOG

alpha.georg@googlemail.com

alpha.georg@googlemail.com
HOLA DOLOR ( ES ) ..:-P

Τετάρτη, 29 Ιουλίου 2009

Gilead Sciences

Gilead Sciences μετάφραση στα ελληνικά


HIV/AIDS


Atripla

Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.GileadHIV.com





Emtriva

Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.GileadHIV.com





Truvada

Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.GileadHIV.com





Viread

Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.GileadHIV.com




Liver Disease


Hepsera

Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.Hepsera.com





Viread

Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.Viread.com




Cardiovascular


Letairis

Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.Letairis.com





Lexiscan

Visit www.Lexiscan.com



Ranexa

Download Full U.S. Prescribing Information, including Important Safety InformationVisit www.Ranexa.com




Respiratory


Tamiflu

Visit www.Tamiflu.com


Other


AmBisome

Download Full U.S. Prescribing Information, including BOXED WARNINGSVisit www.AmBisome.com





Macugen

Visit www.MACUGEN.com



Vistide

Download Full U.S. Prescribing Information, includi




http://www.gilead.com/img/logo.gif



Email:
corporate_development@gilead.com

Mail:
Gilead Sciences
Attn: Corporate Development Department
333 Lakeside Drive
Foster City, CA 94404


Advancing Therapeutics, Improving Lives

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases.

Gilead’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Our portfolio of 12 marketed products includes a number of category firsts and market leaders, including Atripla® (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - the first single-tablet regimen for HIV infection. The company's latest therapy, Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B, was approved in August 2008. Chronic hepatitis B, a serious liver disease caused by the hepatitis B virus, is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States.

More Than 20 Years of Growth

Gilead was founded in 1987 in Foster City, California. In just over 20 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of investigational drugs and approximately 4,000 employees.

In 2008, Gilead’s annual revenues surpassed $5.3 billion. BusinessWeek has ranked Gilead #1 in its 2009 listing of the 50 best-performing companies, up from #2 last year.

Our Marketed Products

Following is a summary of Gilead's product portfolio. See our Products section for full prescribing information, including BOXED WARNINGS and Important Safety Information.

HIV/AIDS

  • Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for the treatment of HIV infection in adults. It is intended for use as a stand-alone therapy, or in combination with other antiretrovirals, and combines Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) with Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb. (U.S. approval, 2006; E.U. approval, 2007.)
  • Emtriva® (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also available as an oral solution for use in pediatric patients. (U.S. and E.U. approval, 2003.)
  • Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread® and Emtriva®. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. (U.S. approval, 2004; E.U. approval, 2005.)
  • Viread® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in adults in combination with other antiretroviral agents. (U.S. approval, 2001; E.U. approval, 2002.)

Liver Disease

  • Hepsera® (adefovir dipivoxil) is a once-daily, oral NtRTI for the treatment of patients with chronic hepatitis B. (U.S. approval, 2002; E.U. approval, 2003.)
  • Viread® (tenofovir disoproxil fumarate) is a once-daily oral NtRTI for the treatment of chronic hepatitis B infection in adults. (U.S. and EU approval, 2008.)

Cardiovascular

  • Letairis® (ambrisentan) is a novel endothelin receptor antagonist (ERA) indicated for the once-daily treatment of PAH (WHO Group 1) in patients with WHO Functional Class II or III symptoms to improve exercise capacity and delay clinical worsening. (U.S. approval, 2007; E.U. approval, 2008.)
  • Lexiscan® (regadenoson) injection is the first A2A adenosine receptor agonist approved by the FDA for use as a pharmacologic stress agent in radionuclide MPI studies. The product has been designed to target the A2A adenosine receptor, which is the adenosine receptor subtype responsible for coronary vasodilation. (U.S. approval, 2008.)
  • Ranexa® (ranolazine) is an extended-release tablet for the treatment of chronic angina. Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors and angiotensin receptor blockers. (U.S. approval, 2006; U.S. expanded indication to include first-line treatment for chronic angina, 2008; E.U. approval, 2008.)

Respiratory

  • Tamiflu® (oseltamivir phosphate) is the first neuraminidase inhibitor tablet for the treatment and prevention of influenza A and B. Tamiflu was approved by the FDA for the treatment of influenza in October 1999 and for influenza prevention in November 2000. Tamiflu has been available in Europe since 2002. The product, which was developed by Gilead, is commercialized globally by Hoffmann-La Roche.

Other

  • AmBisome® (amphotericin B liposome for injection) is a treatment for life-threatening, systemic fungal infections in adults. (E.U. approval, 1990; U.S. approval, 1997.)
  • Macugen® (pegaptanib sodium injection) is an injection for the treatment of neovascular age-related macular degeneration (also known as "wet" AMD), an eye disease that destroys central vision in elderly patients. This product is marketed in the United States by OSI Pharmaceuticals. (U.S. approval, 2004.)
  • Vistide® (cidofovir injection) is an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS. (U.S. approval, 1996; E.U. approval, 1997.)

Growing Worldwide Footprint

Gilead has approximately 4,000 employees around the world. Corporate headquarters are located in Foster City, California. We also have additional operations in:

North American Locations

  • Foster City, CA (Headquarters)
  • Palo Alto, CA
  • San Dimas, CA
  • Boulder, CO
  • Durham, NC
  • Seattle, WA
  • Alberta, Canada
  • Ontario, Canada

International Locations

  • United Kingdom (International Headquarters)
  • Australia/New Zealand
  • Austria
  • Benelux
  • Denmark
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Norway
  • Portugal
  • Spain
  • Sweden
  • Switzerland
  • Turkey

Corporate Responsibility

As Gilead grows as a company, so do our responsibilities as a corporate citizen. We strive to play our part in expanding global access to our medications and to give back to the communities in which we operate.

Gilead recognizes the urgent need for access to HIV medications worldwide, particularly in developing countries where the AIDS epidemic is devastating communities. We believe that the medicines we develop should be accessible to all patients who need them worldwide, regardless of income or location. To date, more than 400,000 patients in the developing world have received Gilead's therapies for the treatment of HIV. We are undertaking the following initiatives to help further expand access to our medicines in resource-limited settings:

  • Gilead Access Program
    Since early 2003, we have operated an access program to provide Viread and Truvada at substantially reduced prices in many low- and middle-income countries.
  • Local Manufacturing in Africa
    In 2005, Gilead entered into a non-exclusive partnership with South Africa-based Aspen Pharmacare, under which Aspen manufactures finished product for access program countries and distributes Gilead therapies throughout Africa.
  • Partnerships with Indian Generic Manufacturers
    Gilead has signed non-exclusive licenses with multiple generic manufacturers in India. Under these agreements, our partners will produce high-quality generic versions of Viread in 95 resource-limited countries, which are home to 95 percent of the world's HIV-infected people. We expect that multiple manufacturers will ensure competitive pricing, thus promoting broad access to our products for patients in developing countries with HIV/AIDS.
  • A Commitment to Research and Development
    Gilead has an active research and development program aimed at identifying new compounds for the treatment of life-threatening diseases (see Research section for more information).
  • Ongoing Research Collaborations
    We are also working with academic, government and private sector partners to better understand the profile of our products in important areas such as pediatric HIV care, prevention of mother-to-child HIV transmission and pre-exposure prophylaxis.
  • Patient Access in the United States
    Gilead supports a number of programs for eligible patients in the United States who do not have insurance, are underinsured or who otherwise need financial assistance. These programs include U.S. Advancing Access®, Atripla® Patient Access Program and Gilead™Solutions.
  • The Gilead Foundation
    Since 2005, the Gilead Foundation has supported more than 80 domestic and international programs, many focused on building local capacity and improving health infrastructure in the developing world. The Foundation also supports disease awareness and education programs in the United States.
  • Support for Community Organizations/Events
    Gilead provides unrestricted grants to non-profit organizations across the United States that advocate for people with serious, life-threatening diseases. In addition, the company sponsors national and local awareness-raising and fund-raising events, such as National HIV Testing Day, local AIDS and Liver Walks and California's AIDS LifeCycle, to name just a few.

Please visit our Corporate Responsibility section for more information on Gilead's work in our communities.

Leadership

Following is a list of Gilead's Executive Committee. See the Leadership section for bios of these individuals as well as Gilead's Board of Directors.

More Information

For more information about Gilead, its products or community involvement, please contact Gilead Public Affairs at +1 (650) 574-3000 or submit a media inquiry online.